Dublin, Ireland-based Horizon Pharma plc is a biopharmaceutical focused on identifying, developing, acquiring and commercializing products that address unmet therapeutic needs in arthritis, pain, inflammatory and orphan diseases. The company operates through three business units – Orphan, Primary Care and Rheumatology. The company’s portfolio currently comprises nine marketed products. Key products include Actimmune (chronic granulomatous disease and severe malignant osteopetrosis) and Duexis (signs and symptoms of osteoarthritis and rheumatoid arthritis) among others.
Meanwhile, Horizon Pharma has been actively pursuing acquisitions to expand and diversify its portfolio. In this scenario, investor focus remains on the company’s performance apart from the usual top-and bottom-line numbers.
Horizon Pharma’s performance has been far from encouraging with the company missing earnings estimates on two occasions while surpassing in one. Yet, the company has an average positive earnings surprise of 4.46%.
Currently, Horizon Pharma has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings Beat: Horizon Pharma’s second-quarter 2016 earnings surpassed expectations. Our consensus called for EPS of 53 cents, and the company reported EPS of 56 cents.
Revenues Beat: Revenues in the reported quarter also came in above expectations. Horizon Pharma posted revenues of $257.4 million, compared to our consensus estimate of $238.1 million.
Key Stats: All three business units – Orphan, Primary Care and Rheumatology – performed well in the second quarter of 2016. Key products including Actimmune drove top-line growth.
2016 Outlook Intact: Horizon Pharma reiterated its net sales and adjusted EBITDA expectations for 2016. The company continues to expect net sales in the range of $1.025 billion to $1.050 billion. It still expects adjusted EBITDA in the range of $495 million to $510 million. The Zacks Consensus Estimate for revenues is $1.02 billion.
Check back later for our full write up on this HZNP earnings report later!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Image: Bigstock
Horizon (HZNP) Beats on Q2 Earnings and Revenue Estimates
Dublin, Ireland-based Horizon Pharma plc is a biopharmaceutical focused on identifying, developing, acquiring and commercializing products that address unmet therapeutic needs in arthritis, pain, inflammatory and orphan diseases. The company operates through three business units – Orphan, Primary Care and Rheumatology. The company’s portfolio currently comprises nine marketed products. Key products include Actimmune (chronic granulomatous disease and severe malignant osteopetrosis) and Duexis (signs and symptoms of osteoarthritis and rheumatoid arthritis) among others.
Meanwhile, Horizon Pharma has been actively pursuing acquisitions to expand and diversify its portfolio. In this scenario, investor focus remains on the company’s performance apart from the usual top-and bottom-line numbers.
Horizon Pharma’s performance has been far from encouraging with the company missing earnings estimates on two occasions while surpassing in one. Yet, the company has an average positive earnings surprise of 4.46%.
Currently, Horizon Pharma has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings Beat: Horizon Pharma’s second-quarter 2016 earnings surpassed expectations. Our consensus called for EPS of 53 cents, and the company reported EPS of 56 cents.
Revenues Beat: Revenues in the reported quarter also came in above expectations. Horizon Pharma posted revenues of $257.4 million, compared to our consensus estimate of $238.1 million.
Key Stats: All three business units – Orphan, Primary Care and Rheumatology – performed well in the second quarter of 2016. Key products including Actimmune drove top-line growth.
2016 Outlook Intact: Horizon Pharma reiterated its net sales and adjusted EBITDA expectations for 2016. The company continues to expect net sales in the range of $1.025 billion to $1.050 billion. It still expects adjusted EBITDA in the range of $495 million to $510 million. The Zacks Consensus Estimate for revenues is $1.02 billion.
Check back later for our full write up on this HZNP earnings report later!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>